is serum-free, the growth of HeLa cells requires serum, so the
N-terminated hydrogelators may interact with some essential
proteins through ionic bonds and consequently inhibit growth
of HeLa cells. This ability to distinguish cancer and normal cells
has not been discovered on any of the C-terminal hydrogelators
(though it is possible for the precursors of hydrogelators18), which
makes it a unique property of the N-terminated hydrogelators
that warrants further investigation.
In conclusion, we design and synthesize a series of dipeptides
based hydrogelators with exposed N-terminal amine that, unlike
their C-terminal analogues, forms hydrogels only within a
narrow pH range. These N-terminated hydrogelators, as a new
group in the family of dipeptide based hydrogelators, not only
provide an alternative option for designing functional hydro-
gelators that allow bioactive groups to be conjugated through
their C-terminals, but also have a unique property of selective
inhibition of the growth of HeLa cells, which is of significance to
the understanding of cellular response to hydrogels and hydro-
gelators and may eventually lead to a route for the applications of
supramolecular hydrogels and hydrogelators in cancer therapies.
This work was partially supported by NIH (R01CA142746).
We thank the EM facility at Brandeis University for assistance.
Fig. 4 The TEM images of negative stained (A) gel I, (B) gel II, (C)
gel III, and (D) the magnified image of the helical nanofibers in gel I.
Notes and references
1 A. Dawn, T. Shiraki, S. Haraguchi, S.-i. Tamaru and S. Shinkai,
Chem.–Asian J., 2011, 6, 266; R. V. Ulijn and A. M. Smith, Chem.
Soc. Rev., 2008, 37, 664; M. Ikeda, R. Ochi, A. Wada and
I. Hamachi, Chem. Sci., 2010, 1, 491.
2 S. Zhang, Nat. Biotechnol., 2004, 22, 151; H. Cui, M. J. Webber
and S. I. Stupp, Biopolymers, 2010, 94, 1.
Fig. 5 48 h cytotoxicity vs. concentration curves of 1–3 on cancerous
3 M. Reches and E. Gazit, Science, 2003, 300, 625; C. H. Goerbitz,
Chem. Commun., 2006, 2332.
cells (HeLa) and counterpart normal cells (Ect1/E6E7).
4 N. M. Sangeetha and U. Maitra, Chem. Soc. Rev., 2005, 34, 821;
Y. Gao, Y. Kuang, Z. F. Guo, Z. H. Guo, I. J. Krauss and B. Xu,
J. Am. Chem. Soc., 2009, 131, 13576; Y. Suzuki, M. Tanihara,
Y. Nishimura, K. Suzuki, Y. Kakimaru and Y. Shimizu,
J. Biomed. Mater. Res., 1998, 42, 112; Z. M. Yang, K. M. Xu,
L. Wang, H. W. Gu, H. Wei, M. J. Zhang and B. Xu, Chem.
Commun., 2005, 4414; K. L. V. Hasırcı, J. D. Gresser, D. L. Wise
and D. J. Trantolo, J. Biotechnol., 2001, 86, 135.
5 S. Yamamichi, Y. Jinno, N. Haraya, T. Oyoshi, H. Tomitori,
K. Kashiwagi and M. Yamanaka, Chem. Commun., 2011, 47, 10344.
6 A. Pal, S. Shrivastava and J. Dey, Chem. Commun., 2009, 6997.
7 Y. Zhang, H. W. Gu, Z. M. Yang and B. Xu, J. Am. Chem. Soc.,
2003, 125, 13680.
8 A. Mahler, M. Reches, M. Rechter, S. Cohen and E. Gazit, Adv.
Mater., 2006, 18,1365;V.Jayawarna,M.Ali,T.A.Jowitt,A.F.Miller,
A. Saiani, J. E. Gough and R. V. Ulijn, Adv. Mater., 2006, 18, 611.
9 X. Yan, Q. He, K. Wang, L. Duan, Y. Cui and J. Li, Angew.
Chem., Int. Ed., 2007, 46, 2431.
10 M. Zhou, A. M. Smith, A. K. Das, N. W. Hodson, R. F. Collins,
R. V. Ulijn and J. E. Gough, Biomaterials, 2009, 30, 2523;
Y. Zhang, Y. Kuang, Y. Gao and B. Xu, Langmuir, 2010, 27, 529.
11 I. Ruckert, A. Demeter, O. Morawski, W. Kuhnle, E. Tauer and
K. A. Zachariasse, J. Phys. Chem. A, 1999, 103, 1958; K. Suzuki,
H. Tanabe, S. Tobita and H. Shizuka, J. Phys. Chem. A, 1997,
101, 4496.
12 H. K. Hall Jr., J. Am. Chem. Soc., 1957, 79, 5441.
13 M. A. Greenfield, J. R. Hoffman, M. Olvera de la Cruz and
S. I. Stupp, Langmuir, 2009, 26, 3641.
14 T. G. Mezger, The rheology handbook: for users of rotational and
oscillatory rheometers, Vincentz Network, 2006.
15 L. L. Frado and R. Craig, J. Mol. Biol., 1992, 223, 391.
16 C.L.Chen,F.C.Hsieh,J.C.Lieblein,J.Brown,C.Chan,J.A.Wallace,
G. Cheng, B. M. Hall and J. Lin, Br. J. Cancer, 2007, 96, 591.
17 P. Vaupel, F. Kallinowski and P. Okunieff, CancerRes., 1989, 49, 6449.
18 Z. M. Yang, K. M. Xu, Z. F. Guo, Z. H. Guo and B. Xu, Adv.
Mater., 2007, 19, 3152.
cytotoxicity towards same cell lines, it is clear that 1, 2 and 3 all
have lower cytotoxicity against Ect1/E6E7 cells than against
HeLa cells (Fig. 5). Same cytotoxicity tests were performed on
another cancer cell line T98G to verify if the cytotoxicity of the
N-terminated hydrogelators only occurs on HeLa cells or is a
general behavior on cancer cells. IC50 values of N-terminated
hydrogelators on T98G (Fig. S1, ESIw) are in the same order of
magnitude with HeLa cells and 2 is also being slightly less toxic
than 1 and 3, which demonstrate that N-terminated hydrogelators
are generally toxic towards cancer cells. 2 differs from the other
two compounds as it has 2-substituted naphthyl instead of the
1-substituted naphthyl group. The cytotoxicity of 2 on HeLa cells
is also lower than that of 1 or 3, thus implying a possible
correlation between substitution patterns with the cytotoxicity.
The difference of the cytotoxicity against the two cell lines
increases with the concentration, and the difference is as large
as 40% (in the case of 3) at the highest concentration tested.
The cause of difference in cytotoxicity of the N-terminated
hydrogelators toward cancer and normal cell lines, we speculate,
unlikely originates from the positive charges provided by the
hydrogelators since the excess of positive charge should also
lead to the death of Ect1/E6E7 cells, but might lie in one or the
combination of the following reasons: first, normal cells might
have a poor permeability to the N-terminated hydrogelators;
second, as acidification is a significant feature of cancer cells,17
normal cells have a pH of 7.4–7.6, so the N-terminated
hydrogelators are less likely to self-assemble in normal cells
than in cancer cells; third, while the growth of Ect1/E6E7 cells
c
This journal is The Royal Society of Chemistry 2011
Chem. Commun., 2011, 47, 12625–12627 12627